What changed for Lupus
A plain English summary of what recently moved in the public data Voxsanity tracks for Lupus. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 13 to 14 (+1)
- Trials recruiting worldwide 228 to 230 (+2)
- Trials on record 1,116 to 1,124 (+8)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Lupus in July 2026. Voxsanity tracks 4 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 86 trials tracked for Lupus that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT02822989 · results posted 8 July 2026
According to the results reported on ClinicalTrials.gov, this trial looked at a device that stimulates the vagus nerve (a major nerve running from the brain to the body) compared to a "sham" version — a fake device used as a control so that neither group knew for certain which treatment they were receiving. A total of 19 people took part: 13 in the vagus nerve stimulation group and 6 in the sham group. Twelve of the 13 in the active group and all 6 in the sham group completed the study. The trial was measuring changes in musculoskeletal (muscle and joint) pain, fatigue, and tender joint counts...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05638802 · results posted 28 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05638802) looked at an investigational medicine called DS-7011a in people with systemic lupus erythematosus (lupus), an autoimmune condition. A total of 25 people took part — 19 received DS-7011a and 6 received a placebo (a dummy treatment with no active ingredient). Of those, 16 in the DS-7011a group and 5 in the placebo group completed the trial. The trial was primarily measuring how many participants experienced unwanted health events (called treatment-emergent adverse events, or new or worsening health problems that ap...
-
NCT01729455 · results posted 20 March 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 2,030 people taking a medicine called Benlysta (belimumab) and 937 people taking other lupus (SLE) medications, for a total of 2,967 participants. The trial was an observational registry study — meaning researchers followed people over time rather than randomly assigning treatments — designed to track specific "adverse events of special interest" (AESIs), which were pre-selected medical events researchers wanted to monitor closely. These included deaths, certain cancers, serious infections, opportunistic infections (i...
-
NCT04971590 · results posted 22 January 2026
According to the results reported on ClinicalTrials.gov, this study enrolled 193 people who had been diagnosed with lupus nephritis (a form of kidney inflammation linked to the autoimmune condition lupus). All 193 participants completed the study. Rather than testing a new treatment, this was an observational study — meaning it was designed to collect detailed information about who these patients were, what symptoms and other health conditions they had, what treatments they were already receiving, and how the condition affected their day-to-day quality of life. The reported data shows a range...
-
NCT04564339 · results posted 22 January 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 123 participants across two separate groups: people with a kidney condition called lupus nephritis (LN) — 38 receiving ravulizumab and 19 receiving a placebo (an inactive treatment) — and people with a kidney condition called IgA nephropathy (IgAN) — 43 receiving ravulizumab and 23 receiving a placebo. The trial was measuring changes in proteinuria, which means the amount of excess protein leaking into the urine — a sign that the kidneys may not be filtering properly. Participants were followed for up to 50 weeks, wit...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05162586 · results posted 1 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05162586) looked at a medicine called enpatoran in people with lupus — a condition where the immune system can attack the body's own tissues. The trial was split into two groups: Cohort A (people with skin-affecting lupus) and Cohort B (people with a broader, more systemic form of lupus). In total, 456 people took part across all groups. Cohort A compared a placebo (a dummy treatment with no active ingredient) against three different doses of enpatoran — 25 mg, 50 mg, and 100 mg — over 16 weeks. Cohort B did the same acros...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05097989 · results posted 15 October 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called ALXN2050 in two separate groups of people with kidney conditions: one group had IgA nephropathy (IgAN), a condition where the immune system damages the kidneys, and the other had lupus nephritis (LN), a kidney complication of the autoimmune disease lupus. In the IgAN group, 9 people received the lower dose (120 mg), 26 received the higher dose (180 mg), and 26 received a placebo (a dummy treatment). In the LN group, 6 received the 120 mg dose, 17 received the 180 mg dose, and 16 received a placebo. The...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03735238 · results posted 10 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,895 people with lupus (also known as systemic lupus erythematosus, or SLE) across multiple specialist clinics in the United States. The trial was testing how well a "patient decision aid" — a tool designed to help people with lupus understand their treatment options and take part in decisions about their care — could be introduced into real-world clinic settings. The study ran from 2019 to 2023, and 1,866 participants completed the study, with 29 not completing it. The reported data shows that the primary measure l...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04835441 · results posted 15 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04835441) enrolled 76 people with systemic lupus erythematosus (lupus) — 38 received the investigational drug acazicolcept (also called ALPN-101) and 38 received a placebo (an inactive treatment). By the end of the study, 33 people in the acazicolcept group and 32 in the placebo group had completed the trial. The trial was measuring safety (through tracking unwanted medical events), as well as how well participants' lupus disease activity responded to treatment, using several established lupus scoring tools. The reported...
-
NCT04908865 · results posted 23 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04908865) enrolled 67 children or young people with lupus (a condition where the immune system attacks the body's own tissues) who received the medicine belimumab. Of those who started, 59 completed the study. The trial tracked participants over 52 weeks and measured things like disease activity using a scoring tool called SELENA-SLEDAI (which runs from 0, meaning no disease activity, to 105, meaning very high activity), as well as doctors' and parents' own ratings of how the condition appeared to be affecting the particip...
-
NCT04294667 · results posted 24 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04294667) enrolled 321 people with lupus — 108 in the placebo plus standard care group and 213 in the investigational treatment (DZP) plus standard care group. The trial's main goal was to measure how many participants met a set of defined criteria for disease improvement — called a "BICLA response" — by week 48. This involved tracking changes in disease activity scores as rated by doctors and specialists, without any worsening in other measures. A number of secondary goals were also tracked at earlier time points and incl...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04128579 · results posted 18 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04128579) tested a drug called EQ001 (also known as itolizumab) across 52 participants in total. Participants were divided into six groups based on either the type of condition they had or the dose they received — ranging from 0.4 mg/kg up to 3.2 mg/kg. The trial's main focus was on tracking unwanted medical events (called "treatment-emergent adverse events") that occurred during the study period, using a standard medical checklist to record them. The reported data shows the number of participants in each group who experi...
-
NCT05048238 · results posted 21 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05048238) enrolled 7 people, all of whom received the drug tofacitinib. Six participants completed the study and one did not. The trial was measuring how tofacitinib affected the skin's response to ultraviolet B (UVB) light — specifically, how many skin cells were dying (a process called apoptosis) after UV exposure, how much UV light was needed to cause visible redness, changes in the activity of inflammation-related genes in the skin, and the severity of skin lupus symptoms as rated by a doctor using a standard scoring t...
-
NCT03915652 · results posted 22 January 2025
According to the results reported on ClinicalTrials.gov, this trial involved 35 people with lupus, split into two groups: 18 in "Wave 1" and 17 in "Wave 2." The trial was testing a care management programme (called Rheum iCMP) aimed at people with lupus, and it measured things like how often participants missed specialist appointments, how often they needed emergency or hospital care, the overall quality of their lupus care, how well they took their medications, their feelings about their medications, and their self-reported lupus disease activity — all tracked over 12 months. The reported da...
-
NCT05123586 · results posted 20 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05123586) enrolled 85 people in total — 42 received a treatment called LY3361237 (at a dose of 450 milligrams) and 43 received a placebo (a dummy treatment with no active ingredient). The trial was looking at whether LY3361237 could reduce symptoms of systemic lupus erythematosus (lupus), specifically joint pain/swelling (arthritis) and skin rash, in people who had those symptoms when they joined the study. The main question the trial set out to answer was how many participants saw those symptoms go into remission (meaning...
-
NCT04451772 · results posted 14 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04451772) involved people with systemic lupus erythematosus (SLE) — a long-term autoimmune condition. A total of 185 participants were enrolled across six groups, each receiving different combinations or doses of two investigational medicines, elsubrutinib and upadacitinib (together called ABBV-599), or placebo versions of one or both. The trial was measuring how many participants experienced medical events after starting treatment (the primary goal), as well as tracking lupus disease activity scores, steroid dose changes,...
-
NCT04181762 · results posted 10 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04181762) enrolled 137 people in the secukinumab 300 mg group and 138 people in the placebo group — 275 participants in total. The trial was measuring whether secukinumab, compared to a placebo (an inactive treatment), could help people with lupus nephritis (a form of kidney disease linked to lupus) achieve certain kidney recovery targets over 52 weeks (about one year). The main thing being measured was something called a "Complete Renal Response" — a combined measure requiring kidney filtration function to be at or near n...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04058028 · results posted 24 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04058028) enrolled 244 adults with systemic lupus erythematosus (lupus) across four groups: 62 received a placebo (a dummy treatment with no active ingredient), 58 received a 70 mg dose of rozibafusp alfa, 36 received a 280 mg dose, and 88 received a 420 mg dose. The trial's main goal was to measure how many participants met a set of pre-defined criteria — known as an "SRI-4 response" — showing improvement in their lupus disease activity at 52 weeks, without their overall condition getting worse in other ways. The reporte...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05430854 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial was an open-label extension (OLE) study — meaning a follow-on phase where all participants received active treatment after a previous trial had ended. A total of 155 people took part across three groups, depending on what they had received in the earlier study: 47 who had previously been on a placebo before switching to daxdilimab every 12 weeks, 57 who had previously received daxdilimab every 4 weeks before continuing on every 12 weeks, and 51 who had been on daxdilimab every 12 weeks throughout. The trial was primarily measu...
-
NCT03845517 · results posted 5 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 350 adults across four groups: 100 received a placebo (a dummy treatment with no active ingredient), 50 received 15 mg of the investigational medicine PF-06700841, 101 received 30 mg, and 99 received 45 mg. All participants had systemic lupus erythematosus (lupus). The trial ran for 52 weeks of treatment followed by a 4-week follow-up period. The main thing being measured was how many participants in each group met a set of standard lupus scoring criteria — known as the SRI-4 — at the end of 52 weeks. This scoring sys...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05232864 · results posted 30 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05232864) enrolled 31 people in total — 16 received secukinumab 300 mg and 15 received a placebo (an inactive dummy treatment). The trial was measuring whether secukinumab could help people achieve what is called a "Complete Renal Response" (CRR) — a combined measure of kidney function that looks at two things: how well the kidneys are filtering blood, and how much protein is leaking into the urine. Notably, the data shows that none of the participants in either group are recorded as having "completed" the study, and all a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03107442 · results posted 22 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03107442) enrolled 58 people in total — 26 in an Exercise group and 32 in a Control group. By the end of the study, 18 people in the Exercise group and 28 in the Control group had completed it, with 8 and 4 people respectively not finishing. The trial was measuring arterial stiffness (how stiff the arteries are, measured by how fast a pulse wave travels through them) as its main focus, along with several blood markers including inflammation, blood sugar, insulin, and a longer-term measure of blood sugar control called HbA1...
-
NCT04141046 · results posted 27 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04141046) looked at a brain stimulation technique called transcranial alternating current stimulation (tACS) — a method that delivers very mild electrical signals to the scalp to try to influence brain activity. The trial had three groups: one that received a "sham" (inactive/pretend) stimulation, one that received stimulation at a "theta" frequency, and one at an "alpha" frequency. In total, only 4 people participated — 1 in the sham group, 0 in the theta-tACS group, and 3 in the alpha-tACS group — and all who started the...
-
NCT00779194 · results posted 12 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT00779194) looked at people with a condition called systemic lupus erythematosus (SLE), which is an autoimmune disease. A total of 43 people with SLE received the study drug, and 56 people without the condition were included as a comparison group (controls). Of the 43 SLE participants, 29 completed the study, while 14 did not finish. The trial was measuring changes in lupus disease activity using two standard scoring tools — the SLEDAI (a 0–105 scale where higher numbers mean more active disease) and the BILAG (a 0–97 scale...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03656562 · results posted 6 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03656562) enrolled 107 people with lupus (systemic lupus erythematosus) across two groups. In the first group (Cohort 1), 34 people received a treatment called VAY736 and 33 received a placebo (an inactive dummy treatment). In the second group (Cohort 2), 20 people received a treatment called CFZ533 and 20 received a placebo. The trial was measuring whether participants met a combined target at week 29: showing meaningful improvement in their lupus disease activity score while also being able to maintain a reduced dose of...
-
NCT04433585 · results posted 23 April 2024
According to the results reported on ClinicalTrials.gov, this trial tested three different doses of a drug called LY3471851 — a high dose, a middle dose, and a low dose — compared to a placebo (a dummy treatment with no active ingredient) in people with lupus, a condition where the immune system attacks the body's own tissues. A total of 291 people took part across the four groups (73 in the high-dose group, 70 in the middle-dose group, 74 in the low-dose group, and 74 in the placebo group). The trial's main goal was to measure how many participants had a meaningful reduction in their lupus di...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04179032 · results posted 26 March 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 25 participants, all of whom received a weekly self-injected dose of belimumab (200 mg). The trial was primarily focused on measuring how much of the drug was present in participants' blood at various points in time — in other words, it was looking at how the body absorbed and held onto the medication, rather than directly measuring whether a disease got better or worse. All 25 participants completed the first phase (up to week 12), 23 of the 25 completed the second phase (up to week 52), and 11 entered an extended ac...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03393013 · results posted 8 March 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03393013) tested an investigational drug called zetomipzomib (also known as KZR-616), given as a weekly injection under the skin, in adults with systemic lupus erythematosus (lupus) — including those with and without kidney involvement (lupus nephritis). The trial ran in two stages: a Phase 1b safety-focused stage, where 47 people were enrolled across six different dosing groups, and a Phase 2 stage, where 22 people took part in a single dosing group. All participants received the study drug alongside their usual standard-...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04186871 · results posted 16 January 2024
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called branebrutinib across three different autoimmune conditions: systemic lupus erythematosus (SLE, a disease where the immune system attacks the body's own tissues), primary Sjögren's syndrome (pSS, a condition affecting moisture-producing glands), and rheumatoid arthritis (RA, a condition causing joint inflammation). In total, 119 people took part — 20 in the SLE groups, 14 in the pSS groups, and 85 in the RA groups. Each condition had participants randomly assigned to receive either branebrutinib or a pla...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03978520 · results posted 21 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03978520) enrolled 341 adults with systemic lupus erythematosus (lupus) across five groups. The groups tested different combinations of two investigational medicines — elsubrutinib and upadacitinib (together called ABBV-599) — against placebo (inactive treatment) or either medicine alone. The trial's main goal was to measure how many participants met a recognised lupus response standard (called SRI-4) *and* had their steroid dose reduced to a low level after 24 weeks. A number of additional measures were also tracked, incl...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 86 reported results for Lupus
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, lupus currently attracts a very large amount of public research funding in the United States, and that investment has been rising year on year. This is an encouraging signal for patients, as sustained and growing public funding generally means researchers are actively pursuing new ways to understand and treat the condition. It suggests the scientific community contin...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.